Cypher $470 Mil. Q4 Domestic Sales Double Size Of Cordis Unit
This article was originally published in The Gray Sheet
Cypher drug-eluting stent U.S. sales propelled a 99% Cordis revenue jump in the fourth quarter to $896 mil
You may also be interested in...
The arguments made by Boston Scientific and Johnson & Johnson/Cordis in the ongoing drug-eluting stent patent dispute both have merit, according to Wilmington, Del. federal court Judge Sue Robinson
Guidant stent sales will not be affected by a June 5 arbitration panel finding that the firm infringed Johnson &Johnson/Cordis' Palmaz-Schatz patents, Guidant says
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker